JP2020022482A5 - - Google Patents

Download PDF

Info

Publication number
JP2020022482A5
JP2020022482A5 JP2019189968A JP2019189968A JP2020022482A5 JP 2020022482 A5 JP2020022482 A5 JP 2020022482A5 JP 2019189968 A JP2019189968 A JP 2019189968A JP 2019189968 A JP2019189968 A JP 2019189968A JP 2020022482 A5 JP2020022482 A5 JP 2020022482A5
Authority
JP
Japan
Prior art keywords
antibody
osmr
composition
binding
binding antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019189968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020022482A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020022482A publication Critical patent/JP2020022482A/ja
Publication of JP2020022482A5 publication Critical patent/JP2020022482A5/ja
Priority to JP2022153731A priority Critical patent/JP7474817B2/ja
Priority to JP2024065396A priority patent/JP7682335B2/ja
Priority to JP2025080667A priority patent/JP2025114801A/ja
Pending legal-status Critical Current

Links

JP2019189968A 2013-05-30 2019-10-17 オンコスタチンm受容体抗原結合タンパク質 Pending JP2020022482A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022153731A JP7474817B2 (ja) 2013-05-30 2022-09-27 オンコスタチンm受容体抗原結合タンパク質
JP2024065396A JP7682335B2 (ja) 2013-05-30 2024-04-15 オンコスタチンm受容体抗原結合タンパク質
JP2025080667A JP2025114801A (ja) 2013-05-30 2025-05-13 オンコスタチンm受容体抗原結合タンパク質

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829082P 2013-05-30 2013-05-30
US61/829,082 2013-05-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017105838A Division JP6606122B2 (ja) 2013-05-30 2017-05-29 オンコスタチンm受容体抗原結合タンパク質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022153731A Division JP7474817B2 (ja) 2013-05-30 2022-09-27 オンコスタチンm受容体抗原結合タンパク質

Publications (2)

Publication Number Publication Date
JP2020022482A JP2020022482A (ja) 2020-02-13
JP2020022482A5 true JP2020022482A5 (enExample) 2020-03-26

Family

ID=51059621

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016517062A Active JP6243521B2 (ja) 2013-05-30 2014-05-30 オンコスタチンm受容体抗原結合タンパク質
JP2017105838A Active JP6606122B2 (ja) 2013-05-30 2017-05-29 オンコスタチンm受容体抗原結合タンパク質
JP2019189968A Pending JP2020022482A (ja) 2013-05-30 2019-10-17 オンコスタチンm受容体抗原結合タンパク質
JP2022153731A Active JP7474817B2 (ja) 2013-05-30 2022-09-27 オンコスタチンm受容体抗原結合タンパク質
JP2024065396A Active JP7682335B2 (ja) 2013-05-30 2024-04-15 オンコスタチンm受容体抗原結合タンパク質
JP2025080667A Pending JP2025114801A (ja) 2013-05-30 2025-05-13 オンコスタチンm受容体抗原結合タンパク質

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016517062A Active JP6243521B2 (ja) 2013-05-30 2014-05-30 オンコスタチンm受容体抗原結合タンパク質
JP2017105838A Active JP6606122B2 (ja) 2013-05-30 2017-05-29 オンコスタチンm受容体抗原結合タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022153731A Active JP7474817B2 (ja) 2013-05-30 2022-09-27 オンコスタチンm受容体抗原結合タンパク質
JP2024065396A Active JP7682335B2 (ja) 2013-05-30 2024-04-15 オンコスタチンm受容体抗原結合タンパク質
JP2025080667A Pending JP2025114801A (ja) 2013-05-30 2025-05-13 オンコスタチンm受容体抗原結合タンパク質

Country Status (23)

Country Link
US (7) US9663571B2 (enExample)
EP (4) EP3456743B1 (enExample)
JP (6) JP6243521B2 (enExample)
KR (3) KR101882366B1 (enExample)
CN (4) CN110511279B (enExample)
AU (5) AU2014273966B2 (enExample)
BR (1) BR112015029643B1 (enExample)
CA (1) CA2910732A1 (enExample)
DK (2) DK3456743T3 (enExample)
EA (1) EA201592285A1 (enExample)
ES (3) ES2895824T3 (enExample)
HU (2) HUE056580T2 (enExample)
IL (3) IL317484A (enExample)
MX (3) MX351127B (enExample)
MY (1) MY199321A (enExample)
NZ (2) NZ753995A (enExample)
PL (3) PL3456743T3 (enExample)
PT (2) PT3456743T (enExample)
SG (1) SG11201508829QA (enExample)
SI (2) SI3456743T1 (enExample)
TR (1) TR201815608T4 (enExample)
WO (1) WO2014194274A2 (enExample)
ZA (1) ZA201508064B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110511279B (zh) 2013-05-30 2024-03-29 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
WO2016120625A1 (en) * 2015-01-29 2016-08-04 Isis Innovation Limited Biomarker
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス, エルエルシー 最適化二重ヌクレアーゼ融合物および方法
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
US10493149B2 (en) * 2017-04-11 2019-12-03 Kiniksa Pharmaceuticals, Ltd. Stable anti-OSMR antibody formulation
WO2019040674A1 (en) * 2017-08-22 2019-02-28 Sanabio, Llc SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
US20210054085A1 (en) * 2018-04-25 2021-02-25 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmrb antibody
WO2020036833A1 (en) * 2018-08-13 2020-02-20 Kiniksa Pharmaceuticals, Ltd. Treatment of skin diseases or disorders by delivery of anti-osmrbeta antibody
US20220002387A1 (en) * 2018-11-06 2022-01-06 University Of Miami Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo
CN110563844A (zh) * 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
TWI904261B (zh) 2020-10-19 2025-11-11 美商碩騰服務公司 犬及貓抑瘤素M受體β之抗體及其用途
KR20240049286A (ko) * 2021-07-30 2024-04-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Osmr-특이적 모노클로날 항체 및 이의 사용 방법
CN119451570A (zh) * 2022-06-29 2025-02-14 百奥赛图(北京)医药科技股份有限公司 一种osm、osmr、il31ra和/或il31基因修饰的非人动物
CN120858115A (zh) 2023-03-07 2025-10-28 基因泰克公司 抗抑瘤素M受体β抗体用于治疗肺纤维化疾病或病症的方法
US20250101117A1 (en) * 2023-09-01 2025-03-27 Genentech, Inc. Methods for treating inflammatory bowel disease
CN120230206A (zh) * 2023-12-29 2025-07-01 苏州爱科百发生物医药技术有限公司 抑瘤素M受体β结合抗体及其用途

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5681930A (en) 1985-12-20 1997-10-28 Bristol-Myers Squibb Company Anti-oncostatin M monoclonal antibodies
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
ZA912136B (en) * 1990-03-29 1992-11-25 Bristol Myers Squibb Co Anti-oncostatin m monoclonal antibodies
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ(renilla)ルシフェラーゼのクローニング及び発現
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
AU762382B2 (en) 1998-09-29 2003-06-26 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU2002216443A1 (en) 2000-12-15 2002-06-24 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region fointerferon beta
ES2330201T3 (es) 2001-01-26 2009-12-07 Selexis S.A. Regiones de union a la matriz y metodos para el uso de las mismas.
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
EP1576112B1 (en) 2002-01-18 2012-02-29 ZymoGenetics, Inc. Cytokine receptor zcytor17 multimers
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP4803789B2 (ja) * 2004-02-03 2011-10-26 独立行政法人科学技術振興機構 疼痛を処置するための薬学的組成物
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス, インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
US7858753B2 (en) 2004-03-30 2010-12-28 Glaxo Group Limited Immunoglobulins
WO2006065533A2 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
JP5328156B2 (ja) * 2005-02-03 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド オンコスタチンmレセプターに対する抗体
CA2594490A1 (en) 2005-02-14 2006-08-24 Zymogenetics Inc. Methods of treating skin disorders using an il-31ra antagonist
KR101446989B1 (ko) 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Il-31 단클론성 항체 및 사용법
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
AU2006247039B2 (en) 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
JP2009503105A (ja) 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
EP1913002B9 (en) 2005-08-09 2012-04-25 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
CA2636288C (en) * 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
CA2643343C (en) 2006-03-01 2015-12-01 Thomson Licensing Device and method for generating a media package
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
RU2009111884A (ru) 2006-09-01 2010-10-10 Займоджинетикс, Инк. (Us) Последовательности вариабельных областей моноклональных антител против il-31 и способы использования
CL2007003291A1 (es) * 2006-11-15 2008-07-04 Medarex Inc Anticuerpo monoclonal humano aislado que enlaza la proteina btla o fragmentos del mismo; acido nucleico que lo codifica; metodo de produccion; composicion e inmunoconjugado que los comprende; y metodo para inhibir el crecimiento de celulas de tumor e
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
WO2010085682A2 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
JP6214010B2 (ja) * 2012-05-11 2017-10-18 公立大学法人和歌山県立医科大学 抗オンコスタチンm受容体ベータ抗体
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN110511279B (zh) 2013-05-30 2024-03-29 基尼克萨制药有限公司 制瘤素m受体抗原结合蛋白
US9550828B2 (en) 2013-09-05 2017-01-24 Boise State University Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
CN110366429B (zh) 2017-03-01 2024-10-11 免疫医疗有限公司 单克隆抗体的配制品
US10493149B2 (en) 2017-04-11 2019-12-03 Kiniksa Pharmaceuticals, Ltd. Stable anti-OSMR antibody formulation

Similar Documents

Publication Publication Date Title
JP2020022482A5 (enExample)
JP2018046872A5 (enExample)
EP2759549A3 (en) IL-31 monoclonal antibodies and methods of use
JP2013198490A5 (enExample)
JP2019110906A5 (enExample)
NZ621483A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
JP2014509837A5 (enExample)
HRP20140266T1 (hr) Postupci inhibiranja vezanja endosijalina na ligande
NZ585622A (en) Hepatitis c virus antibodies
JP2019504032A5 (enExample)
JP2010526028A5 (enExample)
JP2016135783A5 (enExample)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
JP2009225799A5 (enExample)
JP2018505674A5 (enExample)
LTC2041177I2 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
RU2531523C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2018512138A5 (enExample)
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EA201001467A1 (ru) Моноклональное антитело и способ его использования
HRP20221260T1 (hr) Humanizirana i kimerna monoklonska protutijela za cd47
JP2009518005A5 (enExample)
JP2015504421A5 (enExample)
RU2017125758A (ru) Антитела к с5 и способы их применения
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物